Search results
Results from the WOW.Com Content Network
MannKind Corporation is a biopharmaceutical company focusing on the discovery, development, and commercialization of therapeutic products for diseases such as diabetes and pulmonary arterial hypertension. Based in Danbury, Connecticut, the company was founded in February 1991. MannKind Corporation was named after its founder, Alfred E. Mann.
Biopharmaceutical company MannKind (NAS: MNKD) is seeking FDA approval for its inhalable insulin drug, Afrezza. A decision in 2013 is expected, and the company hopes to get this drug to market as ...
You could say that MannKind is treading water a bit these days -- at least from the outside perspective. The company won't announce results from its phase 3 studies of inhalable insulin Afrezza ...
In the video below, he talks with Max Macaluso, the Fool's health care bureau chief, about three companies: Chelsea Therapeutics, MannKind, and Durata Therapeutics, which are looking to launch ...
The clock is ticking for MannKind Corp. (NAS: MNKD) . While the company has long been aiming for FDA approval of its inhaled insulin drug, Afrezza, it is down to its last $25.3 million in cash ...
That appears to be the situation that biotech MannKind (NAS: MNKD) finds itself in these days. Some pharmaceutical companies boast pipelines with dozens of A Garage Sale for MannKind
MannKind took one giant leap over the past few days. Shares have soared more than 30% since last week, after the company reported results for the first quarter. Was the news that great? Not really.
MannKind is in a waiting game. The biotech resubmitted its application to the Food and Drug Administration, responding to issues brought up by the rejection in 2011. The next known catalyst is a ...